Tradjenta is a prescription medication that belongs to the class of dipeptidyl peptidase-4 inhibitors. It is used together with diet and exercise to improve blood glucose control in adults with type 2 diabetes mellitus. The drug works by blocking the enzyme dipeptidyl peptidase-4, which normally breaks down incretin hormones. By inhibiting this enzyme, Tradjenta increases the levels of incretin hormones such as glp-1 and gip in the bloodstream. These hormones stimulate the pancreas to release insulin when glucose levels rise after meals. They also suppress the release of glucagon, a hormone that raises blood glucose, and slow gastric emptying, contributing to lower post-prandial glucose. The combined effect of increased insulin secretion and reduced glucagon leads to lower fasting and post-meal blood sugar levels. Tradjenta does not cause hypoglycemia when used alone, and its action is glucose-dependent, meaning it activates only when blood glucose is elevated.

Tradjenta is the brand name for the drug linagliptin used to manage type 2 diabetes. It belongs to the class of dipeptidase-4 inhibitors that increase levels of incretin hormones. These hormones stimulate the release of insulin from pancreatic cells when blood sugar is high. By enhancing insulin secretion and reducing glucagon output, the medication lowers blood glucose concentrations. The drug acts specifically on the enzyme responsible for breaking down incretin hormones, preventing their rapid degradation. This inhibition prolongs the action of the hormones, leading to improved glycemic control without causing hypoglycemia at recommended doses. Linagliptin is absorbed in the gut and eliminated mainly through the liver with minimal renal dependence. Overall, the pharmacology of Tradjenta provides sustained glucose regulation through a targeted hormonal pathway.

Common side effects of Tradjenta include headache and cough. Some people may experience nasopharyngitis, which is inflammation of the nasopharynx. Urinary tract infections are also reported among users of the medication. Rarely, the drug can cause pancreatitis, though this occurs in a small number of cases. Elevated liver enzymes have been observed in occasional laboratory tests. Most adverse reactions are mild and do not require medical intervention.

Tradjenta may cause headache as a common side effect. Upper respiratory tract infections are frequently observed in patients taking the drug. Nasopharyngitis often occurs alongside cough and mild throat irritation. Some users report dizziness or lightheadedness during treatment. Urinary tract infections are listed among the typical adverse events. Elevated blood amylase levels can be detected in a small percentage of patients. Fatigue and nausea are also reported as relatively common experiences.